Trial Profile
A Phase 1 of JNS002 (Doxorubicin HCl Liposome Injection) in Combination With Bortezomib for Japanese Patients With Relapsed or Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2016
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 25 Jun 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov.
- 26 Mar 2012 Actual patient number (3) added as reported by ClinicalTrials.gov.